Document:

Exhibit

12

Counterpart     of 55
Exhibit 4.43

ENTERGY LOUISIANA, LLC
(successor to Entergy Louisiana, LLC)

TO

THE BANK OF NEW YORK MELLON
(successor to The Chase National Bank of the City of New York)

As Trustee under Entergy Louisiana, LLC’s Mortgage and Deed of Trust 
dated as of April 1, 1944

________________

Ninetieth Supplemental Indenture

Providing among other things for

First Mortgage Bonds, 4.20% Series due September 1, 2048
(Ninety-fourth Series)

Dated as of August 1, 2018

    

NINETIETH SUPPLEMENTAL INDENTURE
Indenture, dated as of August 1, 2018, between ENTERGY LOUISIANA, LLC, a limited liability company of the State of Texas (formerly Entergy Louisiana Power, LLC and hereinafter sometimes called the “Company”), as successor to ENTERGY LOUISIANA, LLC, a limited liability company of the State of Texas organized on December 31, 2005 (hereinafter sometimes called the “Predecessor Company”), successor to ENTERGY LOUISIANA, INC., a corporation of the State of Louisiana converted to a corporation of the State of Texas on December 31, 2005 (hereinafter sometimes called the “Louisiana Company”), which was the successor by merger to LOUISIANA POWER & LIGHT COMPANY, a corporation of the State of Florida (hereinafter sometimes called the “Florida Company”), whose post office address is 4809 Jefferson Highway, Jefferson, Louisiana 70121, and THE BANK OF NEW YORK MELLON, a New York banking corporation (successor to THE CHASE NATIONAL BANK OF THE CITY OF NEW YORK) whose principal corporate trust office is located at 240 Greenwich Street, New York, New York 10286 (hereinafter sometimes called “Trustee”), as Trustee under the Mortgage and Deed of Trust, dated as of April 1, 1944 (hereinafter called the “Mortgage”), which Mortgage was executed and delivered by the Florida Company to secure the payment of bonds issued or to be issued under and in accordance with the provisions of the Mortgage, reference to which Mortgage is hereby made, this Indenture (hereinafter called the “Ninetieth Supplemental Indenture”) being supplemental thereto;
WHEREAS, the Mortgage was recorded in various Parishes in the State of Louisiana, which Parishes are the same Parishes in which this Ninetieth Supplemental Indenture is to be recorded; and
WHEREAS, by the Mortgage, the Florida Company covenanted that it would execute and deliver such supplemental indenture or indentures and such further instruments and do such further acts as might be necessary or proper to carry out more effectually the purposes of the Mortgage and to make subject to the lien of the Mortgage any property thereafter acquired and intended to be subject to the lien thereof; and
WHEREAS, the Florida Company executed and delivered the following supplemental indentures:

	
		
	Designation
	Dated as of

	First Supplemental Indenture 
	March 1, 1948

	Second Supplemental Indenture 
	November 1, 1950

	Third Supplemental Indenture 
	September 1, 1953

	Fourth Supplemental Indenture 
	October 1, 1954

	Fifth Supplemental Indenture 
	January 1, 1957

	Sixth Supplemental Indenture 
	April 1, 1960

	Seventh Supplemental Indenture 
	June 1, 1964

	Eighth Supplemental Indenture 
	March 1, 1966

	Ninth Supplemental Indenture 
	February 1, 1967

	Tenth Supplemental Indenture 
	September 1, 1967

	Eleventh Supplemental Indenture 
	March 1, 1968

	Twelfth Supplemental Indenture 
	June 1, 1969

	Thirteenth Supplemental Indenture 
	December 1, 1969

	Fourteenth Supplemental Indenture 
	November 1, 1970

	Fifteenth Supplemental Indenture 
	April 1, 1971

	Sixteenth Supplemental Indenture 
	January 1, 1972

	Seventeenth Supplemental Indenture 
	November 1, 1972

	Eighteenth Supplemental Indenture 
	June 1, 1973

	Nineteenth Supplemental Indenture 
	March 1, 1974

	Twentieth Supplemental Indenture 
	November 1, 1974

	 
	 

which supplemental indentures were recorded in various Parishes in the State of Louisiana; and
WHEREAS, the Florida Company was merged into the Louisiana Company on February 28, 1975, and the Louisiana Company thereupon executed and delivered a Twenty-first Supplemental Indenture, dated as of March 1, 1975, pursuant to which the Louisiana Company, among other things, assumed and agreed duly and punctually to pay the principal of and interest on the bonds at the time issued and outstanding under the Mortgage, as then supplemented, in accordance with the provisions of said bonds and of any appurtenant coupons and of the Mortgage as so supplemented, and duly and punctually to observe, perform and fulfill all of the covenants and conditions of the Mortgage, as so supplemented, to be kept or performed by the Florida Company, and said Twenty-first Supplemental Indenture was recorded in various Parishes in the State of Louisiana; and
WHEREAS, the Louisiana Company succeeded to and was substituted for the Florida Company under the Mortgage with the same effect as if it had been named as mortgagor corporation therein; and
WHEREAS, the Louisiana Company executed and delivered the following supplemental indentures:

	
		
	Designation
	Dated as of

	Twenty-second Supplemental Indenture 
	September 1, 1975

	Twenty-third Supplemental Indenture 
	December 1, 1976

	Twenty-fourth Supplemental Indenture 
	January 1, 1978

	Twenty-fifth Supplemental Indenture 
	July 1, 1978

	Twenty-sixth Supplemental Indenture 
	May 1, 1979

	Twenty-seventh Supplemental Indenture 
	November 1, 1979

	Twenty-eighth Supplemental Indenture 
	December 1, 1980

	Twenty-ninth Supplemental Indenture 
	April 1, 1981

	Thirtieth Supplemental Indenture 
	December 1, 1981

	Thirty-first Supplemental Indenture 
	March 1, 1983

	Thirty-second Supplemental Indenture 
	September 1, 1983

	Thirty-third Supplemental Indenture 
	August 1, 1984

	Thirty-fourth Supplemental Indenture 
	November 1, 1984

	Thirty-fifth Supplemental Indenture 
	December 1, 1984

	Thirty-sixth Supplemental Indenture 
	December 1, 1985

	Thirty-seventh Supplemental Indenture 
	April 1, 1986

	Thirty-eighth Supplemental Indenture 
	November 1, 1986

	Thirty-ninth Supplemental Indenture 
	May 1, 1988

	Fortieth Supplemental Indenture 
	December 1, 1988

	Forty-first Supplemental Indenture 
	April 1, 1990

	Forty-second Supplemental Indenture 
	June 1, 1991

	Forty-third Supplemental Indenture 
	April 1, 1992

	Forty-fourth Supplemental Indenture 
	July 1, 1992

	Forty-fifth Supplemental Indenture 
	December 1, 1992

	Forty-sixth Supplemental Indenture 
	March 1, 1993

	Forty-seventh Supplemental Indenture 
	May 1, 1993

	Forty-eighth Supplemental Indenture 
	December 1, 1993

	Forty-ninth Supplemental Indenture 
	July 1, 1994

	Fiftieth Supplemental Indenture 
	September 1, 1994

	Fifty-first Supplemental Indenture 
	March 1, 1996

	Fifty-second Supplemental Indenture 
	March 1, 1998

	Fifty-third Supplemental Indenture 
	March 1, 1999

	Fifty-fourth Supplemental Indenture 
	June 1, 1999

	Fifty-fifth Supplemental Indenture 
	May 15, 2000

	Fifty-sixth Supplemental Indenture
	March 1, 2002

	Fifty-seventh Supplemental Indenture
	March 1, 2004

	Fifty-eighth Supplemental Indenture 
	October 1, 2004

	Fifty-ninth Supplemental Indenture
	October 15, 2004

	Sixtieth Supplemental Indenture 
	May 1, 2005

	Sixty-first Supplemental Indenture 
	August 1, 2005

	Sixty-second Supplemental Indenture 
	October 1, 2005

	Sixty-third Supplemental Indenture 
	December 15, 2005

	 
	 

which supplemental indentures were recorded in various Parishes in the State of Louisiana; and
WHEREAS, the Louisiana Company converted into a Texas limited liability company and, pursuant to a Plan of Merger by which the Company and Entergy Louisiana Properties, LLC were created (the “Merger Documents”), underwent a merger by division pursuant to which, among other things, all the Mortgaged and Pledged Property, subject to the Lien of the Mortgage, and all of the rights, obligations and duties of the 

Louisiana Company under the Mortgage, were allocated to the Predecessor Company on December 31, 2005, and the Predecessor Company thereupon executed and delivered a Sixty-fourth Supplemental Indenture, effective as of January 1, 2006, pursuant to which the Predecessor Company, among other things, assumed and agreed duly and punctually to pay the principal of and interest on the bonds at the time issued and outstanding under the Mortgage, as then supplemented, in accordance with the provisions of said bonds and of any appurtenant coupons and of the Mortgage as so supplemented, and duly and punctually to observe, perform and fulfill all of the covenants and conditions of the Mortgage, as so supplemented, to be kept or performed by the Louisiana Company, and said Sixty-fourth Supplemental Indenture was recorded in various Parishes in the State of Louisiana and with the Secretary of State of Texas; and
WHEREAS, effective July 1, 2008, The Bank of New York changed its name to The Bank of New York Mellon; and
WHEREAS, the Predecessor Company executed and delivered the following supplemental indentures:
	
		
	Designation
	Dated as of

	Sixty-fifth Supplemental Indenture 
	August 1, 2008

	Sixty-sixth Supplemental Indenture
	November 1, 2009

	Sixty-seventh Supplemental Indenture
	March 1, 2010

	Sixty-eighth Supplemental Indenture
	September 1, 2010

	Sixty-ninth Supplemental Indenture
	October 1, 2010

	Seventieth Supplemental Indenture
	November 1, 2010

	Seventy-first Supplemental Indenture
	March 1, 2011

	Seventy-second Supplemental Indenture
	April 30, 2011

	Seventy-third Supplemental Indenture
	December 1, 2011

	Seventy-fourth Supplemental Indenture
	January 1, 2012

	Seventy-fifth Supplemental Indenture
	July 1, 2012

	Seventy-sixth Supplemental Indenture
	December 1, 2012

	Seventy-seventh Supplemental Indenture
	May 1, 2013

	Seventy-eighth Supplemental Indenture
	August 1, 2013

	Seventy-ninth Supplemental Indenture
	June 1, 2014

	Eightieth Supplemental Indenture
	July 1, 2014

	Eighty-first Supplemental Indenture
	November 1, 2014

	 
	 

which supplemental indentures were recorded in various Parishes in the State of Louisiana and with the Secretary of State of Texas; and
WHEREAS, effective as of 10:03 A.M. Central Time, October 1, 2015, the Predecessor Company transferred, subject to the Lien of the Mortgage, all or substantially all of the Mortgaged and Pledged Property as an entirety to the Company (the “2015 Transfer”) pursuant to a Plan of Merger between the Predecessor Company and the Company (the “2015 Transfer Documents”), pursuant to which, among other things, the Company succeeded to the ownership of all of the Predecessor Company’s right, title and interest in and to the Mortgaged and Pledged Property as constituted immediately prior to the time that the 2015 Transfer became effective and succeeded to all of the Predecessor Company’s duties and obligations under the Mortgage and the bonds outstanding thereunder;  and 
WHEREAS, upon the 2015 Transfer, the Predecessor Company was released and discharged from all obligations under the Mortgage or any bonds issued thereunder; and

WHEREAS, effective as of 2:02 P.M. Central Time, October 1, 2015, the Company changed its name from “Entergy Louisiana Power, LLC” to “Entergy Louisiana, LLC”;
WHEREAS, the Company executed and delivered an Eighty-second Supplemental Indenture, effective as of October 1, 2015, pursuant to which the Company, among other things, assumed and agreed duly and punctually to pay the principal of and interest on the bonds at the time issued and outstanding under the Mortgage, as then supplemented, in accordance with the provisions of said bonds and of any appurtenant coupons and of the Mortgage as so supplemented, and duly and punctually to observe, perform and fulfill all of the covenants and conditions of the Mortgage, as so supplemented, to be kept or performed by the Predecessor Company thereunder, and said Eighty-second Supplemental Indenture was recorded in various Parishes in the State of Louisiana and with the Secretary of State of Texas; and
WHEREAS, the Company executed and delivered the following supplemental indentures:
	
		
	Designation
	Dated as of

	Eighty-third Supplemental Indenture 
	March 15, 2016

	Eighty-fourth Supplemental Indenture
	March 17, 2016

	Eighty-fifth Supplemental Indenture
Eighty-sixth Supplemental Indenture
Eighty-seventh Supplemental Indenture
	March 17, 2016
August 1, 2016
September 15, 2016

	Eighty-eighth Supplemental Indenture
	May 1, 2017

	Eighty-ninth Supplemental Indenture
	March 1, 2018

	 
	 

which supplemental indentures were recorded in various Parishes in the State of Louisiana and with the Secretary of State of Texas; and
WHEREAS, in addition to the property described in the Mortgage, as supplemented, the Company has acquired certain other property, rights and interests in property; and
WHEREAS, the Florida Company, the Louisiana Company or the Predecessor Company has heretofore issued, in accordance with the provisions of the Mortgage, as supplemented, the following series of bonds:
	
			
	Series
	Principal
Amount
Issued
	Principal
Amount
Outstanding

	3% Series due 1974 
	$ 17,000,000
	None

	3 1/8% Series due 1978 
	10,000,000
	None

	3% Series due 1980 
	10,000,000
	None

	4% Series due 1983 
	12,000,000
	None

	3 1/8% Series due 1984 
	18,000,000
	None

	4 3/4% Series due 1987 
	20,000,000
	None

	5% Series due 1990 
	20,000,000
	None

	4 5/8% Series due 1994 
	25,000,000
	None

	5 3/4% Series due 1996 
	35,000,000
	None

	5 5/8% Series due 1997 
	16,000,000
	None

	6 1/2% Series due September 1, 1997 
	18,000,000
	None

	7 1/8% Series due 1998 
	35,000,000
	None

	9 3/8% Series due 1999 
	25,000,000
	None

	
			
	9 3/8% Series due 2000 
	20,000,000
	None

	7 7/8% Series due 2001 
	25,000,000
	None

	7 1/2% Series due 2002 
	25,000,000
	None

	7 1/2% Series due November 1, 2002 
	25,000,000
	None

	8% Series due 2003 
	45,000,000
	None

	8 3/4% Series due 2004 
	45,000,000
	None

	9 1/2% Series due November 1, 1981 
	50,000,000
	None

	9 3/8% Series due September 1, 1983 
	50,000,000
	None

	8 3/4% Series due December 1, 2006 
	40,000,000
	None

	9% Series due January 1, 1986 
	75,000,000
	None

	10% Series due July 1, 2008 
	60,000,000
	None

	10 7/8% Series due May 1, 1989 
	45,000,000
	None

	13 1/2% Series due November 1, 2009 
	55,000,000
	None

	15 3/4% Series due December 1, 1988 
	50,000,000
	None

	16% Series due April 1, 1991 
	75,000,000
	None

	16 1/4% Series due December 1, 1991 
	100,000,000
	None

	12% Series due March 1, 1993 
	100,000,000
	None

	13 1/4% Series due March 1, 2013 
	100,000,000
	None

	13% Series due September 1, 2013 
	50,000,000
	None

	16% Series due August 1, 1994 
	100,000,000
	None

	14 3/4% Series due November 1, 2014 
	55,000,000
	None

	15 1/4% Series due December 1, 2014 
	35,000,000
	None

	14% Series due December 1, 1992 
	60,000,000
	None

	14 1/4% Series due December 1, 1995 
	15,000,000
	None

	10 1/2% Series due April 1, 1993 
	200,000,000
	None

	10 3/8% Series due November 1, 2016 
	280,000,000
	None

	Series 1988A due September 30, 1988 
	13,334,000
	None

	Series 1988B due September 30, 1988 
	10,000,000
	None

	Series 1988C due September 30, 1988 
	6,667,000
	None

	10.36% Series due December 1, 1995 
	75,000,000
	None

	10 1/8% Series due April 1, 2020 
	100,000,000
	None

	Environmental Series A due June 1, 2021 
	52,500,000
	None

	Environmental Series B due April 1, 2022 
	20,940,000
	None

	7.74% Series due July 1, 2002 
	179,000,000
	None

	8 1/2% Series due July 1, 2022 
	90,000,000
	None

	Environmental Series C due December 1, 2022
	25,120,000
	None

	6% Series due March 1, 2000
	100,000,000
	None

	Environmental Series D due May 1, 2023
	34,364,000
	None

	Environmental Series E due December 1, 2023
	25,991,667
	None

	Environmental Series F due July 1, 2024
	21,335,000
	None

	Collateral Series 1994-A, due July 2, 2017
	117,805,000
	None

	Collateral Series 1994-B, due July 2, 2017
	58,865,000
	None

	Collateral Series 1994-C, due July 2, 2017 
	31,575,000
	None

	8 3/4% Series due March 1, 2026 
	115,000,000
	None

	6 1/2% Series due March 1, 2008 
	115,000,000
	None

	5.80% Series due March 1, 2002 
	75,000,000
	None

	Environmental Series G due June 1, 2030 
	67,200,000
	None

	8 1/2% Series due June 1, 2003 
	150,000,000
	None

	7.60% Series due April 1, 2032 
	150,000,000
	None

	5.5% Series due April 1, 2019 
	100,000,000
	None

	
			
	6.4% Series due October 1, 2034 
	70,000,000
	None

	5.09% Series due November 1, 2014
	115,000,000
	None

	4.67% Series due June 1, 2010 
	55,000,000
	None

	5.56% Series due September 1, 2015 
	100,000,000
	None

	6.3% Series due September 1, 2035 
	100,000,000
	None

	5.83% Series due November 1, 2010 
	150,000,000
	None

	6.50% Series due September 1, 2018
	300,000,000
	300,000,000

	5.40% Series due November 1, 2024
	400,000,000
	400,000,000

	6.0% Series due March 15, 2040
	150,000,000
	None

	4.44% Series due January 15, 2026
	250,000,000
	250,000,000

	Environmental Series H due June 1, 2030 
	119,073,000
	None

	5.875% Series due June 15, 2041
	150,000,000
	None

	4.80% Series due May 1, 2021
	200,000,000
	200,000,000

	1.1007% Series due December 31, 2012
	750,000,000
	None

	1.875% Series due December 15, 2014
	250,000,000
	None

	5.25% Series due July 1, 2052
	200,000,000
	200,000,000

	3.30% Series due December 1, 2022
	200,000,000
	200,000,000

	4.70% Series due June 1, 2063
	100,000,000
	100,000,000

	4.05% Series due September 1, 2023
	325,000,000
	325,000,000

	5% Series due July 15, 2044
	170,000,000
	170,000,000

	3.78% Series due April 1, 2025
	190,000,000
	190,000,000

	4.95% Series due January 15, 2045
LPFA 2016A Series due 2028
LPFA 2016B Series due 2030
	450,000,000
85,681,000
117,852,000
	450,000,000
85,681,000
117,852,000

	3.25% Series due April 1, 2028
	255,000,000
	255,000,000

	Waterford Series due 2017
	51,971,593.98
	None

	4.875% Series due September 1, 2066
2.40% Series due October 1, 2026
	70,000,000
240,000,000
	70,000,000
240,000,000

	3.12% Series due September 1, 2027
	270,000,000
	270,000,000

	 4.00% Series due March 15, 2033
	450,000,000
	450,000,000

	 
	 
	 

which bonds are also hereinafter sometimes called bonds of the First through Ninety-third Series, respectively; and
WHEREAS, Section 8 of the Mortgage provides that the form of each series of bonds (other than the First Series) issued thereunder and of the coupons to be attached to coupon bonds of such series shall be established by Resolution of the Board of Directors of the Company and that the form of such series, as established by said Board of Directors, shall specify the descriptive title of the bonds and various other terms thereof, and may also contain such provisions not inconsistent with the provisions of the Mortgage as the Board of Directors may, in its discretion, cause to be inserted therein expressing or referring to the terms and conditions upon which such bonds are to be issued and/or secured under the Mortgage; and
WHEREAS, Section 120 of the Mortgage provides, among other things, that without the consent of any holders of bonds, the Company and the Trustee, at any time and from time to time, may enter into one or more supplemental indentures, in form satisfactory to the Trustee, in order to establish the form and terms of bonds of any series; and
WHEREAS, the Company now desires to create a new series of bonds and establish the terms of bonds of such series; and

WHEREAS, the execution and delivery by the Company of this Ninetieth Supplemental Indenture, and the terms of the bonds of the Ninety-fourth Series, hereinafter referred to, have been duly authorized by the Board of Directors of the Company by appropriate Resolutions of said Board of Directors;
NOW, THEREFORE, THIS INDENTURE WITNESSETH: That the Company, in consideration of the premises and of One Dollar to it duly paid by the Trustee at or before the ensealing and delivery of these presents, the receipt whereof is hereby acknowledged, and in further evidence of assurance of the estate, title and rights of the Trustee and in order further to secure the payment both of the principal of and interest and premium, if any, on the bonds from time to time issued under the Mortgage, according to their tenor and effect, and the performance of all the provisions of the Mortgage (including any instruments supplemental thereto and any modification made as in the Mortgage provided) and of said bonds, hereby grants, bargains, sells, releases, conveys, assigns, transfers, mortgages, hypothecates, affects, pledges, sets over and confirms (subject, however, to Excepted Encumbrances as defined in Section 6 of the Mortgage, as supplemented) unto The Bank of New York Mellon, as Trustee under the Mortgage, as supplemented, and to its successor or successors in said trust, and to said Trustee and its successors and assigns forever, (a) all of the Mortgaged and Pledged Property acquired by the Company from the Predecessor Company pursuant to the 2015 Transfer Documents, and improvements, extensions and additions thereto and renewals and replacements thereof, (b) the property made and used by the Company as the basis under any of the provisions of the Mortgage, as supplemented, for the authentication and delivery of additional bonds or the withdrawal of cash or the release of property, and (c) such franchises, repairs and additional property as may be acquired, made or constructed by the Company (1) to maintain, renew and preserve the franchises covered by this Mortgage, as supplemented, or (2) to maintain the property mortgaged and intended to be mortgaged under the Mortgage, as supplemented, as an operating system or systems in good repair, working order and condition, or (3) in rebuilding or renewal of property, subject to the Lien of the Mortgage, as supplemented, damaged or destroyed, or (4) in replacement of or substitution for machinery, apparatus, equipment, frames, towers, poles, wire, pipe, tools, implements and furniture, subject to the Lien of the Mortgage, as supplemented, which shall have become old, inadequate, obsolete, worn out, unfit, unadapted, unserviceable, undesirable or unnecessary for use in the operation of the property mortgaged and intended to be mortgaged under the Mortgage, as supplemented.
PROVIDED THAT the following are not and are not intended to be now or hereafter granted, bargained, sold, released, conveyed, assigned, transferred, mortgaged, hypothecated, affected, pledged, set over or confirmed hereunder and are hereby expressly excepted from the lien and operation of this Ninetieth Supplemental Indenture and Mortgage, as supplemented, and from the lien and operation of the Mortgage, namely: (1) cash, shares of stock, bonds, notes and other obligations and other securities not hereafter specifically pledged, paid, deposited, delivered or held under the Mortgage or covenanted so to be; (2) merchandise, equipment, materials or supplies held for the purpose of sale in the usual course of business and fuel, oil and similar materials and supplies consumable in the operation of any properties of the Company; rolling stock, buses, motor coaches, automobiles and other vehicles and all aircraft; (3) bills, notes and accounts receivable, judgments, demands and choses in action, and all contracts, leases and operating agreements not specifically pledged under the Mortgage or covenanted so to be; (4) the last day of the term of any lease or leasehold which may hereafter become subject to the lien of the Mortgage; (5) electric energy, gas, ice, and other materials or products generated, manufactured, produced or purchased by the Company for sale, distribution or use in the ordinary course of its business; all timber, minerals, mineral rights and royalties; (6) the Company’s franchise to be a corporation; and (7) any property heretofore released pursuant to any provisions of the Mortgage; provided, however, that the property and rights expressly excepted from the lien and operation of the Mortgage in the above subdivisions (2) and (3) shall (to the extent permitted by law) cease to be so excepted in the event and as of the date that the Trustee or its successor or successors in said trust or a receiver or trustee shall enter upon and take possession of the Mortgaged and Pledged Property 

in the manner provided in Article XIII of the Mortgage by reason of the occurrence of a Default as defined in Section 65 thereof.
TO HAVE AND TO HOLD all such properties, real, personal and mixed, granted, bargained, sold, released, conveyed, assigned, transferred, mortgaged, hypothecated, affected, pledged, set over or confirmed by the Company as aforesaid, or intended so to be, unto The Bank of New York Mellon, as Trustee, and its successors and assigns forever.
IN TRUST NEVERTHELESS, for the same purposes and upon the same terms, trusts and conditions and subject to and with the same provisos and covenants as are set forth in the Mortgage, as supplemented, this Ninetieth Supplemental Indenture being supplemental thereto.
AND IT IS HEREBY COVENANTED by the Company that all the terms, conditions, provisos, covenants and provisions contained in the Mortgage, as supplemented, shall affect and apply to the property hereinbefore described and conveyed and to the estate, rights, obligations and duties of the Company and the Trustee and the beneficiaries of the trust with respect to said property, and to the Trustee and its successors as Trustee of said property in the same manner and with the same effect as if said property had been owned by the Florida Company at the time of the execution of the Mortgage, and had been specifically and at length described in and conveyed to said Trustee by the Mortgage as a part of the property therein stated to be conveyed.
The Company further covenants and agrees to and with the Trustee and its successor or successors in said trust under the Mortgage as follows:
ARTICLE I

NINETY-FOURTH SERIES BONDS

SECTION 1    There shall be a series of bonds designated “4.20% Series due September 1, 2048” (herein sometimes called the “Ninety-fourth Series”), each of which shall also bear the descriptive title “First Mortgage Bond”, and the form thereof, which has been established by Resolution of the Board of Directors of the Company, is attached hereto as Exhibit A. Bonds of the Ninety-fourth Series (which shall be initially issued in the aggregate principal amount of $360,000,000) shall be dated as in Section 10 of the Mortgage provided, shall mature on September 1, 2048, shall be issued as fully registered bonds in any integral multiple or multiples of One Thousand Dollars, and shall bear interest at the rate of 4.20% per annum, the first interest payment to be made on March 1, 2019, for the period from August 14, 2018 to March 1, 2019 with subsequent interest payments payable semiannually on March 1 and September 1 of each year (each, an “Interest Payment Date”), the principal of and interest on each said bond to be payable at the office or agency of the Company in the Borough of Manhattan, The City of New York, in such coin or currency of the United States of America as at the time of payment is legal tender for public and private debts. Interest on the bonds of the Ninety-fourth Series shall be paid to the Person in whose name such bonds of the Ninety-fourth Series are registered.

Interest on the bonds of the Ninety-fourth Series will be computed on the basis of a 360-day year of twelve 30-day months.  In any case where any Interest Payment Date, redemption date or the maturity date of any bond of the Ninety-fourth Series shall not be a Business Day, then payment of interest or principal and premium, if any, need not be made on such date, but may be made on the next succeeding Business Day, with the same force and effect, and in the same amount, as if made on the corresponding Interest Payment Date, redemption date, or at maturity, as the case may be, and, if such payment is made or duly provided for on such Business Day, no interest shall accrue on the amount so payable for the period from and after such 

Interest Payment Date, redemption date or the maturity date, as the case may be, to such Business Day.  “Business Day” means any day, other than a Saturday or a Sunday, or a day on which banking institutions in The City of New York are authorized or required by law or executive order to remain closed or a day on which the corporate trust office of the Trustee is closed for business.
The bonds of the Ninety-fourth Series shall be issued by the Company, registered in the name of and delivered to The Bank of New York Mellon, as trustee (together with its successors as trustee under the Collateral Trust Mortgage referenced below, the “Collateral Trust Trustee”) under the Mortgage and Deed of Trust of the Company dated as of November 1, 2015 as the same may be supplemented and amended from time to time (the “Collateral Trust Mortgage”), to provide for the payment when due (whether at maturity, by acceleration or otherwise) of the principal and interest of the Securities (as defined in the Collateral Trust Mortgage) to be issued from time to time under the Collateral Trust Mortgage.
Any payment by the Company under the Collateral Trust Mortgage of the principal of or interest on the Securities which shall have been authenticated and delivered under the Collateral Trust Mortgage on the basis of the issuance and delivery to the Collateral Trust Trustee of bonds of the Ninety-fourth Series (other than by application of the proceeds of a payment in respect of such bonds) shall, to the extent of such payment, be deemed to satisfy and discharge the obligation of the Company, if any, to make a payment of principal of,  or interest on such bonds, as the case may be, which is then due. 
The Trustee may conclusively presume that the obligation of the Company to pay the principal of and interest on the bonds of the Ninety-fourth Series as the same shall become due and payable shall have been fully satisfied and discharged unless and until it shall have received a written notice from the Collateral Trust Trustee signed by its President, a Vice President, an Assistant Vice President or a Trust Officer, stating that interest or principal due and payable on any Securities issued under the Collateral Trust Mortgage has not been fully paid and specifying the amount of funds required to make such payment. 
(I) Each holder of a bond of the Ninety-fourth Series consents that the bonds of the Ninety-fourth Series may be redeemed at the option of the Company or pursuant to the requirements of the Mortgage in whole at any time, or in part from time to time, prior to maturity, without notice provided in Section 52 of the Mortgage, at the principal amount of the bonds to be redeemed, in each case, together with accrued interest to the date fixed for redemption by the Company in a notice delivered to the Trustee and to the holder of the bonds to be redeemed on or before the date fixed for redemption.
The bonds of the Ninety-fourth Series shall be redeemed, in whole at any time, or in part from time to time, prior to maturity, at a redemption price equal to the principal amount thereof, upon receipt by the Trustee of a written notice from the Collateral Trust Trustee (i) delivered to the Trustee and the Company, (ii) signed by its President, a Vice President, an Assistant Vice President or a Trust Officer, (iii) stating that an Event of Default has occurred and is continuing under the Collateral Trust Mortgage and that, as a result, there then is due and payable a specified amount with respect to the Securities Outstanding under the Collateral Trust Mortgage, for the payment of which the Collateral Trust Trustee has not received funds, and (iv) specifying the principal amount of the bonds of the Ninety-fourth Series to be redeemed.  Delivery of such notice shall constitute a waiver by the Collateral Trust Trustee of notice of redemption under the Mortgage. 
(II) The bonds of the Ninety-fourth Series shall not be transferable by the Collateral Trust Trustee, except to a successor trustee under the Collateral Trust Mortgage.  Bonds of this series so transferable to a successor trustee under the Collateral Trust Mortgage may be transferred by the registered owner thereof, in person, or by his duly authorized attorney, at the office or agency of the Company in the Borough of Manhattan, The City of New York, in the manner prescribed in the Mortgage.  

At the option of the registered owner, any bonds of the Ninety-fourth Series, upon surrender thereof for cancellation at the office or agency of the Company in the Borough of Manhattan, The City of New York, shall be exchangeable for a like aggregate principal amount of bonds of the Ninety-fourth Series of other authorized denominations.
Upon any exchange or transfer of bonds of the Ninety-fourth Series, the Company may make a charge therefor sufficient to reimburse it for any tax or taxes or other governmental charge, as provided in Section 12 of the Mortgage, but the Company hereby waives any right to make a charge in addition thereto for any exchange or transfer of bonds of said Series.
(III) Upon the delivery of this Ninetieth Supplemental Indenture and upon compliance with the applicable provisions of the Mortgage, as heretofore supplemented, there shall be an initial issue of bonds of the Ninety-fourth Series for the aggregate principal amount of $360,000,000.  Additional bonds of the Ninety-fourth Series, without limitation as to amount, having substantially the same terms as the Outstanding bonds of the Ninety-fourth Series (except for the issue date and, if applicable, the initial Interest Payment Date) may be issued by the Company, subject to satisfaction of the requirements of the Mortgage, as heretofore supplemented, without notice to or the consent of the existing holders of the bonds of the Ninety-fourth Series.

ARTICLE II

CONSENT TO AMENDMENTS

SECTION 1    Each initial and future holder of bonds of the Ninety-fourth Series, by its acquisition of an interest in such Bonds, irrevocably (a) consents to the amendment set forth in Sections 1, 2, 3, 4 and 5 of Article II of the Eighty-first Supplemental Indenture to the Mortgage dated as of November 1, 2014, without any other or further action by any holder of such bonds, and (b) designates the Trustee, and its successors, as its proxy with irrevocable instructions to vote and deliver written consents on behalf of such holder in favor of such amendments at any bondholder meeting, in lieu of any bondholder meeting, in any consent solicitation or otherwise.

ARTICLE III

MISCELLANEOUS PROVISIONS

SECTION 1    Subject to any amendments provided for in this Ninetieth Supplemental Indenture, the terms defined in the Mortgage, as heretofore supplemented, shall, for all purposes of this Ninetieth Supplemental Indenture, have the meanings specified in the Mortgage, as heretofore supplemented.

SECTION 2    So long as any bonds of the Ninety-fourth Series shall remain Outstanding, in each Net Earning Certificate made pursuant to Section 7 of the Mortgage there shall be included in operating expenses for the twelve (12) months period with respect to which such certificate is made an amount, if any (not otherwise included), equal to the provisions for amortization of any amounts included in utility plant acquisition adjustment accounts for such period. 
    
SECTION 3    So long as any bonds of the Ninety-fourth Series shall remain Outstanding, subdivision (2) of Section 7(A) of the Mortgage is hereby amended by adding thereto the following words “provided, further, that the amount so included in such operating expenses in lieu of the amounts actually appropriated 

out of income for retirement of the Mortgaged and Pledged Property used primarily and principally in the electric, gas, steam and/or hot water utility business and the Company’s automotive equipment used in the operation of such property shall not be less than the amounts so actually appropriated out of income”.

SECTION 4    The Trustee hereby accepts the trusts herein declared, provided, created or supplemented and agrees to perform the same upon the terms and conditions herein and in the Mortgage, as heretofore amended, set forth and upon the following terms and conditions: 

The Trustee shall not be responsible in any manner whatsoever for or in respect of the validity or sufficiency of this Ninetieth Supplemental Indenture or for or in respect of the recitals contained herein, all of which recitals are made by the Company solely. In general, each and every term and condition contained in Article XVII of the Mortgage, as heretofore amended, shall apply to and form part of this Ninetieth Supplemental Indenture with the same force and effect as if the same were herein set forth in full with such omissions, variations and insertions, if any, as may be appropriate to make the same conform to the provisions of this Ninetieth Supplemental Indenture.
SECTION 5    Whenever in this Ninetieth Supplemental Indenture any of the parties hereto is named or referred to, this shall, subject to the provisions of Articles XVI and XVII of the Mortgage, as heretofore amended, be deemed to include the successors and assigns of such party, and all covenants and agreements in this Ninetieth Supplemental Indenture contained by or on behalf of the Company, or by or on behalf of the Trustee, shall, subject as aforesaid, bind and inure to the respective benefits of the respective successors and assigns of such parties, whether so expressed or not. 

SECTION 6    Nothing in this Ninetieth Supplemental Indenture, expressed or implied, is intended, or shall be construed, to confer upon, or give to, any person, firm or corporation, other than the parties hereto and the holders of the bonds and coupons Outstanding under the Mortgage, any right, remedy or claim under or by reason of this Ninetieth Supplemental Indenture or any covenant, condition, stipulation, promise or agreement hereof, and all the covenants, conditions, stipulations, promises and agreements in this Ninetieth Supplemental Indenture contained by or on behalf of the Company shall be for the sole and exclusive benefit of the parties hereto, and of the holders of the bonds and coupons Outstanding under the Mortgage. 

SECTION 7    It is the intention and it is hereby agreed that, so far as concerns that portion of the Mortgaged and Pledged Property situated within the State of Louisiana, the general language of conveyance contained in this Ninetieth Supplemental Indenture is intended and shall be construed as words of hypothecation and not of conveyance, and that, so far as the said Louisiana property is concerned, this Ninetieth Supplemental Indenture shall be considered as an act of mortgage and pledge under the laws of the State of Louisiana, and the Trustee herein named is named as mortgagee and pledgee in trust for the benefit of itself and of all present and future holders of bonds and coupons issued and to be issued under the Mortgage, and is irrevocably appointed special agent and representative of the holders of the bonds and coupons issued and to be issued under the Mortgage and vested with full power in their behalf to effect and enforce the mortgage and pledge hereby constituted for their benefit, or otherwise to act as herein provided for. 

SECTION 8    This Ninetieth Supplemental Indenture shall be executed in several counterparts, each of which shall be an original and all of which shall constitute but one and the same instrument.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

IN WITNESS WHEREOF, ENTERGY LOUISIANA, LLC has caused its company name to be hereunto affixed, and this instrument to be signed and sealed by its President or one of its Vice Presidents, its Treasurer or one of its Assistant Treasurers, and its company seal to be attested by its Secretary or one of its Assistant Secretaries, for and in its behalf, and THE BANK OF NEW YORK MELLON, in token of its acceptance of the trust hereby created, has caused its corporate name to be hereunto affixed, and this instrument to be signed and sealed by one of its Vice Presidents, Senior Associates or Associates and its corporate seal to be attested by one of its Vice Presidents, Senior Associates or Associates, all as of the day and year first above written.
	
		
	 
	ENTERGY LOUISIANA, LLC

By:  /s/ Steven C. McNeal
Name: Steven C. McNeal
Title:   Vice President and Treasurer

	Attest:

By: /s/ Dawn A. Balash
Name: Dawn A. Balash
Title:   Assistant Secretary
	 

	Executed, sealed and delivered by
ENTERGY LOUISIANA, LLC
in the presence of:

/s/ Mary Beth Rose
Name: Mary Beth Rose
/s/ Kyle Michael Joseph
Name: Kyle Michael Joseph
	 

	
		
	 
	THE BANK OF NEW YORK MELLON
As Successor Trustee

By:  /s/ Francine Kincaid
Name: Francine Kincaid
Title:   Vice President

	Attest:

By: /s/ Ignazio Tamburello
Name: Ignazio Tamburello
Title:  Vice President
	 

	Executed, sealed and delivered by
THE BANK OF NEW YORK MELLON
in the presence of:

/s/ Thomas Hacker
Name: Thomas Hacker

/s/ Glenn McKeever
Name: Glenn McKeever
	 

STATE OF LOUISIANA
                                                    } ss.:
PARISH OF ORLEANS
On this 10th day of August, 2018, before me appeared STEVEN C. MCNEAL, to me personally known, who, being by me duly sworn, did say that he is Vice President and Treasurer of ENTERGY LOUISIANA, LLC, and that the seal affixed to the above instrument is the seal of said entity and that said instrument was signed and sealed in behalf of said entity by authority of its Board of Directors, and said STEVEN C. MCNEAL, acknowledged said instrument to be the free act and deed of said entity.
On this 10th day of August, 2018, before me personally came STEVEN C. MCNEAL, to me known, who, being by me duly sworn, did depose and say that he resides at 8043 Winner’s Circle, Mandeville, LA 70448; that he is Vice President and Treasurer of ENTERGY LOUISIANA, LLC, one of the entities described in and which executed the above instrument; that she knows the seal of said entity; that the seal affixed to said instrument is such seal, that it was so affixed by order of the Board of Directors of said entity, and that he signed his name thereto by like order.
	
		
	 
	 

	 
	/s/ Jennifer B. Favalora
Notary Public
Name: Jennifer B. Favalora
Notary ID Number 57639
Parish of Jefferson, State of Louisiana
My commission expires: at my death

        

STATE OF NEW YORK
                                                            } ss.:
COUNTY OF NEW YORK
On this 9th day of August, 2018, before me appeared Francine Kincaid, to me personally known or proved to me on the basis of satisfactory evidence and, who, being by me duly sworn, did say that she is a Vice President of THE BANK OF NEW YORK MELLON, and that the seal affixed to the above instrument is the corporate seal of said entity and that said instrument was signed and sealed in behalf of said entity by authority of its Board of Directors, and said Vice President acknowledged said instrument to be the free act and deed of said entity.
On this 9th day of August, 2018, before me personally came Ignazio Tamburello, to me known or proved to me on the basis of satisfactory evidence and, who, being by me duly sworn, did depose and say that he resides in Beth Page, New York; that he is a Vice President of THE BANK OF NEW YORK MELLON, one of the entities described in and which executed the above instrument; that he knows the seal of said entity; that the seal affixed to said instrument is such seal, that it was so affixed by order of the Board of Directors of said entity, and that he signed his name thereto by like order.

/s/ Bret S. Derman            
Bret S. Derman
Notary Public State of New York
No. 02DE6196933
Qualified in Kings County
Certificate Filed in New York County
Commission Expires November 17, 2020

EXHIBIT A

This Bond is not transferable except to a successor trustee under the Collateral Trust Mortgage (as defined below) between Entergy Louisiana, LLC and the Collateral Trust Trustee (as defined below).  This Bond is a Class A Bond (as defined in the Collateral Trust Mortgage) issued under the ELL Mortgage (as defined in the Collateral Trust Mortgage).
(TEMPORARY REGISTERED BOND)
ENTERGY LOUISIANA, LLC
First Mortgage Bond, 4.20% Series due September 1, 2048
                 
TR-    $________
ENTERGY LOUISIANA, LLC, a limited liability company of the State of Texas (hereinafter called the “Company”), for value received, hereby promises to pay to THE BANK OF NEW YORK MELLON, as trustee under the Mortgage and Deed of Trust of the Company dated as of November 1, 2015 (as the same may be supplemented and amended from time to time, the “Collateral Trust Mortgage”), or its successor as trustee under the Collateral Trust Mortgage, on September 1, 2048, at the office or agency of the Company in the Borough of Manhattan, The City of New York,

in such coin or currency of the United States of America as at the time of payment is legal tender for public and private debts, and to pay to the registered owner hereof interest thereon from August 14, 2018, if the date of this bond is prior to March 1, 2019, or if the date of this bond is on or after March 1, 2019, from the March 1 or September 1 immediately preceding the date of this bond to which interest has been paid on the bonds of this series (unless the date hereof is an interest payment date to which interest has been paid, in which case from the date hereof), at the rate of 4.20% per annum in like coin or currency at said office or agency on March 1 and September 1 of each year, commencing March 1, 2019 until the principal of this bond shall have become due and payable, and to pay interest on any overdue principal and (to the extent that payment of such interest is enforceable under applicable law) on any overdue installment of interest at the rate of 6% per annum.   Interest hereon shall be paid to the Person in whose name this bond is registered.
Interest on the bonds of this series will be computed on the basis of a 360-day year of twelve 30-day months.  In any case where any Interest Payment Date, redemption date or the maturity date of any bond of this series shall not be a Business Day, then payment of interest or principal and premium, if any, need not be made on such date, but may be made on the next succeeding Business Day, with the same force and effect, and in the same amount, as if made on the corresponding Interest Payment Date, redemption date, or at maturity, as the case may be, and, if such payment is made or duly provided for on such Business Day, no interest shall accrue on the amount so payable for the period from and after such Interest Payment Date, redemption date or the maturity date, as the case may be, to such Business Day.  “Business Day” means any day, other than a Saturday or a Sunday, or a day on which banking institutions in The City of New York are authorized or required by law or executive order to remain closed or a day on which the corporate trust office of the Trustee is closed for business.
This bond is a temporary bond and is one of an issue of bonds of the Company issuable in series and is one of a series known as its First Mortgage Bonds, 4.20% Series due September 1, 2048, all bonds of all series issued and to be issued under and equally secured (except insofar as any sinking or other fund, established in accordance with the provisions of the Mortgage hereinafter mentioned, may afford additional security for the bonds of any particular series) by the Company’s Mortgage and Deed of Trust (herein, together with any indenture supplemental thereto, 

including the Ninetieth Supplemental Indenture dated as of August 1, 2018, called the “Mortgage”), dated as of April 1, 1944, executed by the Company to The Bank of New York Mellon, successor trustee (the “Trustee”).  Reference is made to the Mortgage for a description of the property mortgaged and pledged, the nature and extent of the security, the rights of the holders of the bonds and of the Trustee in respect thereof, the duties and immunities of the Trustee, the terms and conditions upon which the bonds are and are to be secured, the circumstances under which additional bonds may be issued and the rights of the Company to amend the Mortgage without any consent or other action by the holders of any series of bonds (including this series).  With the consent of the Company and to the extent permitted by and as provided in the Mortgage, the rights and obligations of the Company and/or the rights of the holders of the bonds and/or coupons and/or the terms and provisions of the Mortgage may be modified or altered by such affirmative vote or votes of the holders of bonds then outstanding as are specified in the Mortgage. Each initial and future holder of the bonds of this series, by its acquisition of an interest in such bonds, irrevocably (a) consents to the amendments set forth in Article II of the Eighty-first Supplemental Indenture without any other or further action by any holder of such bonds, and (b) designates the Trustee, and its successors, as its proxy with irrevocable instructions to vote and deliver written consents on behalf of such holder in favor of such amendments at any bondholder meeting, in lieu of any bondholder meeting, in any consent solicitation or otherwise.
The bonds of this series shall be issued by the Company, registered in the name of and delivered to The Bank of New York Mellon, as trustee under the Collateral Trust Mortgage, or its successor as trustee under the Collateral Trust Mortgage (collectively, the “Collateral Trust Trustee”), to provide for the payment when due (whether at maturity, by acceleration or otherwise) of the principal and interest of the Securities (as defined in the Collateral Trust Mortgage) to be issued from time to time under the Collateral Trust Mortgage.
Any payment by the Company under the Collateral Trust Mortgage of the principal of or interest on the Securities which shall have been authenticated and delivered under the Collateral Trust Mortgage on the basis of the issuance and delivery to the Collateral Trust Trustee of bonds of this series (other than by application of the proceeds of a payment in respect of such bonds) shall, to the extent of such payment, be deemed to satisfy and discharge the obligation of the Company, if any, to make a payment of principal of,  or interest on such bonds, as the case may be, which is then due. 
The Trustee may conclusively presume that the obligation of the Company to pay the principal of and interest on this bond as the same shall become due and payable shall have been fully satisfied and discharged unless and until it shall have received a written notice from the Collateral Trust Trustee signed by its President, a Vice President, an Assistant Vice President or a Trust Officer, stating that interest or principal due and payable on any Securities issued under the Collateral Trust Mortgage has not been fully paid and specifying the amount of funds required to make such payment. 
The holder of this bond hereby consents that the bonds of this series may be redeemable at the option of the Company or pursuant to the requirements of the Mortgage in whole at any time, or in part from time to time, prior to the maturity date, without notice provided in Section 52 of the Mortgage, at the principal amount of the bonds to be redeemed, in each case, together with accrued interest to the date fixed for redemption by the Company in a notice delivered to the Trustee and to the holder of the bonds to be redeemed on or before the date fixed for redemption.
The bonds of this series shall be redeemed, in whole at any time, or in part from time to time, prior to the maturity date, at a redemption price equal to the principal amount thereof, upon receipt by the Trustee of a written notice from the Collateral Trust Trustee (i) delivered to the Trustee and the Company, (ii) signed by its President, a Vice President, an Assistant Vice President or a Trust Officer, (iii) stating that an Event of Default has occurred and is continuing under the Collateral Trust Mortgage and that, as a result, there then is due and payable a specified amount with respect to the Securities Outstanding under the Collateral Trust Mortgage, for the payment of which the Collateral Trust Trustee has not received funds, and (iv) specifying the principal amount of the bonds of this series to be redeemed.  Delivery of such notice shall constitute a waiver by the Collateral Trust Trustee of notice of redemption under the Mortgage.

The principal hereof may be declared or may become due prior to the maturity date hereinbefore named on the conditions, in the manner and at the time set forth in the Mortgage, upon the occurrence of a default as in the Mortgage provided.
This bond is not transferable except to any successor trustee under the Collateral Trust Mortgage, any such transfer to be made in the manner prescribed in the Mortgage, by the registered owner hereof in person, or by his duly authorized attorney, at the office or agency of the Company in the Borough of Manhattan, The City of New York, upon surrender and cancellation of this bond, together with a written instrument of transfer whenever required by the Company duly executed by the registered owner or by his duly authorized attorney, and thereupon a new fully registered bond of the same series for a like principal amount will be issued to the transferee in exchange herefor as provided in the Mortgage.  
The Company and the Trustee may deem and treat the person in whose name this bond is registered as the absolute owner hereof for the purpose of receiving payment and for all other purposes and neither the Company nor the Trustee shall be affected by any notice to the contrary.
In the manner prescribed in the Mortgage, any bonds of this series, upon surrender thereof, for cancellation, at the office or agency of the Company in the Borough of Manhattan, The City of New York, are exchangeable for a like aggregate principal amount of bonds of the same series of other authorized denominations.  
Upon any transfer or exchange of bonds of this series, the Company may make a charge therefor sufficient to reimburse it for any tax or taxes or other governmental charge, as provided in Section 12 of the Mortgage, but the Company hereby waives any right to make a charge in addition thereto for any exchange or transfer of bonds of this series. 
In the manner prescribed in the Mortgage, this temporary bond is exchangeable at the office or agency of the Company in the Borough of Manhattan, The City of New York, without charge, for a definitive bond or bonds of the same series of a like aggregate principal amount when such definitive bonds are prepared and ready for delivery.
As provided in the Mortgage, the Company shall not be required to make transfers or exchanges of bonds of any series for a period of ten days next preceding any interest payment date for bonds of said series, or next preceding any designation of bonds of said series to be redeemed, and the Company shall not be required to make transfers or exchanges of any bonds designated in whole or in part for redemption.
No recourse shall be had for the payment of the principal of or interest on this bond against any incorporator or any  past, present or future subscriber to the capital stock, stockholder, officer or director of the Company or of any predecessor or successor corporation, as such, either directly or through the Company or any predecessor or successor corporation, under any rule of law, statute or constitution or by the enforcement of any assessment or otherwise, all such liability of incorporators, subscribers, stockholders, officers and directors being released by the holder or owner hereof by the acceptance of this bond and being likewise waived and released by the terms of the Mortgage.
This bond shall not become obligatory until The Bank of New York Mellon, the Trustee under the Mortgage, or its successor thereunder, shall have signed the form of authentication certificate endorsed hereon.

IN WITNESS WHEREOF, ENTERGY LOUISIANA, LLC has caused this bond to be signed in its company name by its President or one of its Vice Presidents by his or her signature or a facsimile thereof, and its company seal to be impressed or imprinted hereon and attested by its Secretary or one of its Assistant Secretaries by his or her signature or a facsimile thereof.
DATED: ____________                ENTERGY LOUISIANA, LLC

By:__________________________________________            
Vice President and Treasurer
Attest:

________________________________

Assistant Secretary

TRUSTEE’S AUTHENTICATION CERTIFICATE
This bond is one of the bonds, of the series herein designated, described or provided for in the within-mentioned Mortgage.
THE BANK OF NEW YORK MELLON
as Trustee
By:_________________________________________
Authorized Signatory

Dated: ______________Exhibit

Exhibit 10.1

Execution Copy

THIS AGREEMENT AND ANY SECURITIES ISSUABLE PURSUANT HERETO HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT OR AN EXEMPTION THEREFROM.

Genome Protection, Inc.
SAFE
(Simple Agreement for Future Equity)
THIS SIMPLE AGREEMENT FOR FUTURE EQUITY (THIS “AGREEMENT”), DATED AS OF August 10, 2018, CERTIFIES THAT in exchange for the payment in instalments by Norma Investments Limited, a British Virgin Islands company (the “Investor”) of up to US$30,000,000.00 (the “Purchase Amount”) as specified herein, Genome Protection, Inc., a Delaware corporation (the “Company”), hereby grants to the Investor the right to certain shares of the Company’s capital stock, subject to the terms set forth below. The first installment of the Purchase Amount of US$10,500,000.00 is payable within 3 business days from the date of execution of this Agreement. The subsequent installments shall be made in the amount and within the timeframe determined in a drawdown request by the Company made after the corresponding decision of the Board of Directors, provided the Investor shall be given at least 10 business days’ prior written notice of the requirement to make any payment. It is preliminarily intended that one further instalment shall be advanced at the beginning of 2019 and a further final instalment shall be advanced at the beginning of 2020, but this remains subject to approval by the Board of Directors. The Company shall use the Purchase Amount in accordance with the budget and business plan prepared by the Company, as may be amended from time to time by the Board of Directors of the Company.
In order to induce Investor to enter into this Agreement, Cleveland Biolabs, Inc., a Delaware corporation, (“CBLI”) and Everon Biosciences, Inc., a New York corporation, (“Everon” and, together with CBLI, the “Shareholders”) each hereby irrevocably and unconditionally, jointly and severally, guarantee to the extent of their powers as shareholders of the Company the due and punctual performance by the Company of all of the Company’s obligations hereunder. 
		
	1.
	Events.

(a)Equity Financing.  If there is an Equity Financing at any time after the date of execution of this Agreement by the Company and the Investor, then the Investor shall have the right to require the Company to issue to the Investor and the Company shall have the right to require the Investor to accept the number of shares of Preferred Stock of the Company (the “New Round Stock”) obtained by dividing (x) the Purchase Amount actually paid to the Company hereunder by (y) 50% of the price per share of the Preferred Stock sold in the Equity Financing.
In connection with the issuance of such shares of New Round Stock to the Investor pursuant to Section 1(a): (i) the Investor will execute and deliver to the Company customary subscription, purchase and other documents related to the New Round Stock; provided, that such documents shall be substantially similar to the documents to be entered into with the purchasers of the Preferred Stock sold in the Equity Financing, and provided further that such documents shall include only limited representations and warranties and limited liability and indemnification obligations on the part of the Investor; (ii) the Investor and the Company will execute a Pro Rata Rights Agreement, unless the Investor is already included in such rights in the transaction documents related to the Equity Financing.
(b)Dissolution Event.  If there is a Dissolution Event before this Agreement expires or terminates, the Company will pay an amount equal to the Purchase Amount actually disbursed by the Investor to the Investor immediately prior to, or concurrent with, the consummation of the Dissolution Event. The Purchase Amount will be paid prior and in preference to any Distribution of any of the assets of the Company to holders of outstanding Capital Stock by reason of their ownership thereof. If immediately prior to the 

SIMPLE AGREEMENT FOR FUTURE EQUITY

consummation of the Dissolution Event, the assets of the Company legally available for distribution to the Investor, as determined in good faith by the Company’s board of directors, are insufficient to permit the payment to the Investor of the Purchase Amount actually disbursed by the Investor, then the entire assets of the Company legally available for distribution will be distributed to the Investor to the extent necessary to satisfy the Company’s obligation hereunder.
(c)Termination.  This Agreement will expire and terminate (without relieving the Company of any obligations arising from a prior breach of or non-compliance with this Agreement) upon (i) the issuance of New Round Stock to the Investor pursuant to Section 1(a), (ii) payment in full by the Company of the Purchase Amount actually disbursed upon the occurrence of a Dissolution Event pursuant to Section 1(b), (iii) the payment in full by the Company of the Purchase Amount and/or the issuance of shares of Capital Stock pursuant to Section 1(d) or (iv) if Investor so chooses, pursuant to Section 7(b). Following such termination, the Investor will have no rights to any Capital Stock and the Company shall have no obligation to issue the Investor any Capital Stock, in each case pursuant to the terms of this Agreement and without prejudice to any other rights the Investor may have.
(d)Liquidity Event.  If there is a Liquidity Event before the expiration or termination of this Agreement in accordance with subsection (c) above, the Investor will, at its option either: (i) receive a cash payment equal to the Purchase Amount actually disbursed by the Investor and accrued interest on the Purchase Amount at 6.33 percent per year, accrued on each tranche of the Purchase Amount starting from the date each such tranche was transferred to the bank account of the Company (subject to the following paragraph) by giving at least 10 business days’ prior written notice or, if the Investor does not select the option of cash payment according to subsection (i) then; (ii)  at the written request of the Investor, will promptly issue to the Investor, effective as of immediately prior to the occurrence of the Liquidity Event, a number of shares of Common Stock obtained by dividing (x) the Purchase Amount actually disbursed by the Investor by (y) 50% of the price per share determined by the Company’s pre-money valuation on the day before Liquidity Event (as determined by the Company in its reasonable judgment).
In connection with Section 1(d)(i), the Purchase Amount actually disbursed by the Investor will be due and payable by the Company to the Investor immediately prior to, or concurrent with, the consummation of the Liquidity Event. If there are not enough funds to pay the Investor in full, then all of the Company’s available funds will be disbursed to the Investor and the Investor will automatically receive the number of shares of Common Stock obtained by dividing (x) the remaining unpaid Purchase Amount actually disbursed by the Investor (plus accrued interest) by 50% of the price per share determined by the Company’s pre-money valuation on the day before Liquidity Event (as determined by the Company in its reasonable judgment), in each case, only to the extent necessary to satisfy the Company’s obligation under Section 1(d)(i). In connection with a Change of Control intended to qualify as a tax-free reorganization, the Company may reduce, pro rata, the Purchase Amount actually disbursed by the Investor (plus accrued interest) payable to the Investor by the amount determined by its board of directors in good faith to be advisable for such Change of Control to qualify as a tax-free reorganization for U.S. federal income tax purposes, and in such case, the Investor will automatically receive the number of shares of Common Stock equal to the remaining unpaid Purchase Amount actually disbursed by the Investor (plus accrued interest) divided by the price determined as described in this Section hereof.

SIMPLE AGREEMENT FOR FUTURE EQUITY

		
	2.
	Definitions.

(a)“Affiliate” means in relation to any person, any other person directly or indirectly Controlled by, or Controlling, or under common Control with, that person and, in the case of a trust, any trustee or beneficiary (actual or potential) of that trust and, in the case of an individual, any “Close Family Member” (i.e. any spouse or civil partner (former or present), parents (and those of his or her spouse or civil partner), descendants (including any child, whether by blood, adoption or marriage), siblings, aunts, uncles, cousins, nephews, or nieces) of such individual; and (without limitation to the generality of the foregoing) with respect to any person directly or indirectly Controlled by a trust (a “Controlling Trust”), an “Affiliate” of that person includes any beneficiary of such Controlling Trust, any Close Family Member of a beneficiary of such Controlling Trust and any other person directly or indirectly Controlled by, or under common Control, with (a) a beneficiary of such Controlling Trust or a Close Family Member of a beneficiary; or (b) a separate trust, with a beneficiary in common with such Controlling Trust or a beneficiary who is a Close Family Member of such Controlling Trust. For the purpose of this definition, “Control” means the power of a person to secure, directly or indirectly, (whether by the holding of shares, possession of voting rights or by virtue of any other power conferred by the articles of association, constitution, partnership deed or other documents regulating another person or otherwise) that the affairs of such other person are conducted in accordance with his or its wishes and “Controlled” and “Controlling” shall be construed accordingly.
(b)“Capital Stock” means the capital stock of the Company, including, without limitation, the Common Stock and the Preferred Stock.
(c)“Change of Control” means: (i) a transaction or series of related transactions in which any “person” or “group” (within the meaning of Section 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended), becomes the “beneficial owner” (as defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended), directly or indirectly, of more than 50% of the outstanding voting securities of the Company having the right to vote for the election of members of the Company’s board of directors; (ii) any reorganization, merger or consolidation of the Company, other than a transaction or series of related transactions in which the holders of the voting securities of the Company outstanding immediately prior to such transaction or series of related transactions retain, immediately after such transaction or series of related transactions, at least a majority of the total voting power represented by the outstanding voting securities of the Company or such other surviving or resulting entity; or (iii) a sale, lease or other disposition of all or substantially all of the assets of the Company.
(d)“Common Stock” means the common stock of the Company.
(e)“Distribution” means the transfer to holders of Capital Stock by reason of their ownership thereof of cash or other property without consideration whether by way of dividend or otherwise, other than dividends on Common Stock payable in Common Stock, or the purchase or redemption of Capital Stock by the Company or its subsidiaries for cash or property other than: (i) repurchases of Common Stock held by employees, officers, directors or consultants of the Company or its subsidiaries pursuant to an agreement providing, as applicable, a right of first refusal or a right to repurchase shares upon termination of such service provider’s employment or services; or (ii) repurchases of Capital Stock in connection with the settlement of disputes with any stockholder.
(f)“Dissolution Event” means: (i) a voluntary termination of operations; (ii) a general assignment for the benefit of the Company’s creditors; or (iii) any other liquidation, dissolution or winding up of the Company (excluding a Liquidity Event), whether voluntary or involuntary.
(g)“Equity Financing” means a bona fide transaction or series of transactions with person(s) other than current shareholders of the Company and/or the Investor and its Affiliates with the principal purpose of raising capital, pursuant to which the Company issues and sells shares Preferred Stock at a fixed pre-money valuation and with aggregate proceeds of not less than US$3,000,000.  For the avoidance of doubt, any part of the Purchase Amount or any other amount provided under this SAFE shall not be considered an Equity Financing.
(h)“Initial Public Offering” means the closing of the Company’s first firm commitment underwritten initial public offering of Common Stock pursuant to a registration statement filed under the Securities Act.
(i)“Liquidity Event” means a Change of Control, except for Change of Control resulting from the Equity Financing described in Section 1(a), or an Initial Public Offering.
(j)“New Round Stock” means the Preferred Stock .
(k)“Preferred Stock” means preferred stock of the Company.
(l)“Pro Rata Rights Agreement” means a written agreement between the Company and the Investor (and holders of other SAFEs, as appropriate) giving the Investor a right to purchase its pro rata share of private 

SIMPLE AGREEMENT FOR FUTURE EQUITY

placements of securities by the Company occurring after the Equity Financing, subject to customary exceptions. Pro rata for purposes of the Pro Rata Rights Agreement will be calculated based on the ratio of (1) the number of shares of Capital Stock owned by the Investor immediately prior to the issuance of the securities occurring after the Equity Financing to (2) the total number of shares of Capital Stock on a fully diluted basis, calculated as of immediately prior to the issuance of the securities.
(m)“SAFE” means an instrument containing a future right to shares of Capital Stock, similar in form and content to this Agreement, purchased by investors for the purpose of funding the Company’s business operations.
(n)“Subsequent Convertible Securities” means convertible securities that the Company may issue after the issuance of this instrument with the principal purpose of raising capital, including but not limited to, other SAFES, convertible debt instruments and other convertible securities. 
3.“MFN” Amendment Provision. If the Company issues any Subsequent Convertible Securities prior to termination of this Agreement, the Company will promptly provide the Investor with written notice thereof, together with a copy of all documentation relating to such Subsequent Convertible Securities and, upon written request of the Investor, any additional information related to such Subsequent Convertible Securities as may be reasonably requested by the Investor. In the event the Investor determines that the terms of the Subsequent Convertible Securities are preferable to the terms of this Agreement, the Investor will notify the Company in writing. Promptly after receipt of such written notice from the Investor, the Company agrees to amend and restate this Agreement to be identical to the instrument(s) evidencing the Subsequent Convertible Securities.
		
	4.
	Corporate Governance.

(a)Notwithstanding any other provision of this Agreement to the contrary, from the date of the that the Company receives the first tranche of the Purchase Amount in an amount not less than $10,500,000 from the Investor until the termination of this Agreement pursuant to its terms or otherwise:
		
	(i)
	the board of directors of the Company shall consist of a maximum of four directors, two of whom shall be appointed by the Investor pursuant to subsection (iii) below, one of whom shall be appointed by CBLI (each such director, and any successor or replacement nominated by the Investor, an “CBLI Director”) and one of whom shall be appointed by Everon (each such director, and any successor or replacement nominated by the Investor, an “Everon Director”);

		
	(ii)
	and at least one Investor Director (as defined below) must be present or otherwise participate (as provided for in subsection (vii) below) provided that a quorum shall not be less than one-third of all directors then in office at any board meeting for it to be deemed quorate, except that if due notice of a board meeting has been given and a quorum is not present within half an hour from the time appointed for the meeting: the board meeting shall be adjourned to such time and place as the directors of the Company shall determine; the directors of the Company must reconvene the board meeting and give at least three days’ notice of the reconvened meeting stating the date, time and place of the board meeting; and if no quorum is present at the reconvened board meeting within fifteen minutes of the time specified for the start of the board meeting the directors present in person or by proxy at that time shall constitute the quorum for that board meeting;

		
	(iii)
	the Investor shall have the right to appoint two of the four directors of the Company (each such director, and any successor or replacement nominated by the Investor, an “Investor Director”);

		
	(iv)
	if any of Investor Director from time to time resigns or otherwise ceases to be a director of the Company, then the Investor shall have the right to appoint a replacement director to the board of directors of the Company to fill such vacancy; 

		
	(v)
	A Director may at any time appoint any person who is qualified to be appointed as Director (who may also be a serving Director or an alternate Director of the Company), to act as a substitute or alternate for him ("Alternate Director") at any meeting at which the appointing Director is not present. Every appointment or removal of Alternate Director shall be made in writing or by telegram, e-mail or by facsimile, delivered to the Company.

		
	(vi)
	Subject to the provisions of subsection (ii) above in respect to adjourned meeting, unless all of the Directors at that time agree to a shorter notice, or waive notice altogether, every Director shall be given at least ten (10) days’ notice (by letter, facsimile, email or phone) regarding the time and place at which any meeting of the Directors shall be held.

		
	(vii)
	Subject to the provisions of the Law, the Directors shall be entitled to hold their meetings by use of 

SIMPLE AGREEMENT FOR FUTURE EQUITY

any means of communication, provided that all participating Directors are able to hear each other at the same time.
		
	(viii)
	each Investor Director shall be entitled to be a member of any committee of the board of directors whether now existing or hereafter established, except that such Investor Directors will not be entitled to participate in deliberations and decisions relating to any dealings or transactions between the Company and the Investor or that otherwise present a conflict of interest for such Investor Directors;

		
	(ix)
	the following matters will require unanimous approval of the elected directors of the Company (which, for the avoidance of doubt, must include the affirmative vote of both Investor Directors):

		
	A.
	the entry into an agreement or agreements providing for, or consummation of, any Change of Control;

		
	B.
	the entry into an agreement or agreements providing for, or consummation of, any Dissolution Event; 

		
	C.
	any amendment to the Certificate of Incorporation or Bylaws of the Company; and

		
	D.
	transferring, licensing or assigning (out of the ordinary course of business) any intellectual property rights of the Company, including without limitation, the transfer or licensing (out of the ordinary course of business) of any patents, know how or trade secrets of the Company, and any applications relating thereto, or entering into any agreement with any third party with respect to the transfer of any material scientific or technical information;

		
	E.
	any sale or issuance of Capital Stock, including the granting of any options, convertible debt or any other instrument that gives or purports to give someone a right to any equity in the Company, except issuances of Capital Stock pursuant to this Agreement or any other Simple Agreement for Future Equity entered into with the prior approval of the board of directors of the Company.

		
	(x)
	the following matters will require approval of a majority of the elected directors of the Company:

		
	•
	incurring or permitting to subsist any aggregate financial indebtedness in excess of US$100,000, including by way of guaranteeing obligations of any other party, that is not already included in a budget approved by the board of directors of the Company (including the Investor Directors), except for its obligations under this Agreement;

		
	•
	granting security over or otherwise encumbering any of its assets; 

		
	•
	entering into or being a party to any transaction with any director, officer, or employee of the Company or any “associate” (as defined in Rule 12b-2 promulgated under the Exchange Act) of any such Person, except for transactions contemplated by this Agreement; 

		
	•
	hiring, terminating, or changing the compensation of the executive officers of the Company, including approving any option grants or stock awards to executive officers;

		
	•
	changing the principal business of the Company, entering new lines of business, or exiting the current line of business; and

		
	•
	transferring, licensing or assigning (out of the ordinary course of business) any material asset of the Company other than intellectual property rights.

		
	(xi)
	all other matters i) not specified in paragraphs (viii) or (ix) below; ii) not within the exclusive powers of the shareholders of the Company and/or iii)  not delegated to the officers of the Company shall require approval of a majority of the elected directors of the Company (which, for the avoidance of doubt, must include the affirmative vote of at least one Investor Director).

5.Company Representations.  The Company, CLBI  and Everon each hereby represents and warrants to the Investor as of the date hereof as follows:
(a)The Company is a corporation duly organized, validly existing and in good standing under the laws of the state of its incorporation, and has the power and authority to own, lease and operate its properties and carry on its business as now conducted.
(b)The execution, delivery and performance by the Company of this Agreement is within the power of the Company and, other than with respect to the actions to be taken when equity is to be issued to the Investor, has been duly authorized by all necessary actions on the part of the Company. This Agreement constitutes a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except as limited by bankruptcy, insolvency or other laws of general application relating to or affecting the enforcement of creditors’ rights generally and general principles of equity. To the knowledge of the Company, it is not in violation of: (i) its current certificate of incorporation or bylaws, (ii) any material statute, rule or regulation applicable to the 

SIMPLE AGREEMENT FOR FUTURE EQUITY

Company or (iii) any material indenture or contract to which the Company is a party or by which it is bound, where, in each case, such violation or default, individually, or together with all such violations or defaults, could reasonably be expected to have a material adverse effect on the Company, its business, prospects or financial condition and results of operation.
(c)The performance and consummation by the Company of the transactions contemplated by this Agreement do not:
		
	(i)
	violate any material judgment, statute, rule or regulation applicable to the Company;

		
	(ii)
	result in the acceleration of any material indenture or contract to which the Company is a party or by which it is bound; or 

		
	(iii)
	result in the creation or imposition of any lien upon any property, asset or revenue of the Company or the suspension, forfeiture, or nonrenewal of any material permit, license or authorization applicable to the Company, its business or operations.

(d)No consents or approvals are required in connection with the performance of this Agreement, other than:
		
	(i)
	the Company’s corporate approvals;

		
	(ii)
	any qualifications or filings under applicable securities laws; and

		
	(iii)
	necessary corporate approvals for the authorization of Capital Stock issuable pursuant to Section 1.

(e)As of the date hereof, the capital structure of the Company is follows: the only Capital Stock issued and outstanding is Common Stock; 1,000 shares of Common Stock (constituting 50% of the entire issued and outstanding Common Stock) are owned by CBLI; and 1,000 shares of Common Stock (constituting 50% of the entire issued and outstanding Common Stock) are owned by Everon Biosciences, Inc.. There are no outstanding options, warrants, rights (including conversion or preemptive rights and rights of first refusal), proxy or shareholders agreements, or agreements of any kind (oral or written) for the purchase or acquisition from the Company of any Capital Stock, except for this Agreement and  Simple Agreement for Future Equity for $275,000 between the Company and M.A. Mogutov.
(f)The Company has not agreement, obligation or commitment with respect to the election of any individual or individuals to its board of directors and there be no voting agreement or other arrangement among the Company’s stockholders, except for this Agreement;
(g)The Company has no debts, liabilities or monetary obligations to any Person in excess of US$10,000 in the aggregate. Since incorporation of the Company, the operations and business of the Company have been conducted in all respects only in the ordinary course of business and the Company has not entered into any transaction which was not in the ordinary course of its business.
(h)There is no action, suit or proceeding, or governmental inquiry or investigation, pending, or, to the Company’s knowledge, threatened, against the Company, its assets, or any officer, director or employee of the Company, which questions the validity of this Agreement or the right of the Company to enter into any such agreements, or which would reasonably be expected to have a material adverse effect on the Company, its business or financial condition and results of operation. There is no action, suit, proceeding or investigation by the Company currently pending or that the Company intends to initiate.
The Company owns or possesses sufficient legal rights to all patents, trademarks, service marks, trade names, copyrights, trade secrets, licenses, information, processes; know-how and other intellectual property rights necessary for its business as now conducted and without any conflict with, or infringement or misappropriation of the rights of, others and, to the  Company’s knowledge, free and clear from all liens. Without limitation to the generality of the foregoing, the Company currently owns, free and clear from all liens, or is the valid license holder of, the intellectual property rights as listed in Exhibit 1 hereto.
(i)All information supplied by or on behalf of the Company to the Investor or its representatives prior to the execution of this Agreement was true, complete and accurate in all respects at its date and did not omit any information which, if disclosed, might adversely affect the Investor’s decision to enter into this Agreement and nothing has occurred since the date of such information which renders it untrue or misleading in any respect. 
6.Investor Representations.  The Investor hereby represents and warrants to the Company as follows:
(a)The Investor has full legal capacity, power and authority to execute and deliver this 

SIMPLE AGREEMENT FOR FUTURE EQUITY

Agreement and to perform its obligations hereunder. This Agreement constitutes valid and binding obligation of the Investor, enforceable in accordance with its terms, except as limited by bankruptcy, insolvency or other laws of general application relating to or affecting the enforcement of creditors’ rights generally and general principles of equity.
(b)The Investor is an accredited investor as such term is defined in Rule 501 of Regulation D under the Securities Act. The Investor has been advised that this Agreement and the underlying securities have not been registered under the Securities Act, or any state securities laws and, therefore, cannot be resold unless they are registered under the Securities Act and applicable state securities laws or unless an exemption from such registration requirements is available. The Investor is purchasing this Agreement and the securities to be acquired by the Investor hereunder for its own account for investment, not as a nominee or agent, and not with a view to, or for resale in connection with, the distribution thereof, and the Investor has no present intention of selling, granting any participation in, or otherwise distributing the same. The Investor has such knowledge and experience in financial and business matters that the Investor is capable of evaluating the merits and risks of such investment, is able to incur a complete loss of such investment without impairing the Investor’s financial condition and is able to bear the economic risk of such investment for an indefinite period of time. The Investor is not a person or entity, or an Affiliate of a person or entity, subject to sanction, embargo or trade restriction imposed by the United States government, including, without, limitation, any person or entity on (i) the Consolidated Screening List maintained at www.export.gov and (ii) the U.S. Treasury Department’s Office of Foreign Assets Control sanctions program list.
(c)The Investor acknowledges that it has received all the information it considers necessary or appropriate to enable it to make an informed decision concerning an investment in the Company through this Agreement and any shares of Capital Stock it acquires in connection with this Agreement. The Investor further represents that it has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the offering of the Company’s securities. The Investor confirms that the Company has not given any guarantee or representations as to the potential success, return, effect or benefit of an investment in the Company’s securities. In deciding to invest in the Company, the Investor is not relying on the advice or recommendations of the Company or CBLI or any of its or their Affiliates or representatives and has made its own independent decision that the investment is suitable and appropriate for the Investor. 
		
	(d)
	The Investor understands that this Agreement and the shares of Capital Stock issuable hereunder have not been, and will not be, registered under the Securities Act or state securities laws, by reason of specific exemptions from the registration provisions thereof which depend upon, among other things, the bona fide nature of the investment intent and the accuracy of the Investor’s representations as expressed herein. The Investor understands that such securities are “restricted securities” under U.S. federal and applicable state securities laws and that, pursuant to these laws, the Investor must hold the Securities indefinitely unless they are registered with the Securities and Exchange Commission and registered or qualified by state authorities, or an exemption from such registration and qualification requirements is available. The Investor acknowledges that the Company has no obligation to register or qualify the securities for resale and further acknowledges that, if an exemption from registration or qualification is available, it may be conditioned on various requirements including, but not limited to, the time and manner of sale, the holding period for the Securities, and on requirements relating to the Company which are outside of the Investor’s control, and which the Company is under no obligation, and may not be able, to satisfy. The Investor understands that no public market now exists for the Company’s securities and that the Company has made no assurances that a public market will ever exist for such securities.

7.Subsequent Financing from the Investor.
(a)In the event that the Investor or an Affiliate of the Investor subsequently decide(s) to provide additional investments to the Company or an Affiliate of the Company within the framework of a Simple Agreement for Future Equity (a “New SAFE”), then the Company and the Investor agree that the terms of any New SAFE that are more favorable to the Investor in any material respect shall apply to all SAFEs previously made by and between the Company and the Investor, except as such terms relate to temporal matters relating to the date of this Agreement.
(b)In the event that the Investor or an Affiliate of the Investor subsequently decide(s) to provide additional investments to the Company or an Affiliate of the Company in the form of equity financing, other than a New SAFE, pursuant to a separate agreement (a “New Financing Agreement”), then the Company agrees that the Investor shall have the option (in its sole and absolute discretion) to require the Company to treat the Purchase 

SIMPLE AGREEMENT FOR FUTURE EQUITY

Amount actually disbursed by the Investor as monies provided under the New Financing Agreement, rather than this SAFE. If the Investor notifies the Company in writing that it wishes to exercise the aforementioned option, the Company shall enter into any and all documentation necessary or desirable to give effect to this and, upon the entering into force of such documentation, this SAFE shall terminate and be of no further force and effect.
8.Miscellaneous.
(a)Any provision of this Agreement may be amended, waived or modified only upon the written consent of the Company and the Investor.
(b)The Investor shall transmit the Purchase Amount in US Dollars by wire transfer to the following Company’s bank account or another account that may be from time to time communicated by the Company:

Beneficiary: Genome Protection, Inc.
Bank:  Key Bank
Bank Address: 50 Fountain Plaza, Buffalo, NY 14202, USA
SWIFT:  KEYBUS33
ABA Routing Number:  021300077
Account Number:  320071001608
(c)Any notice required or permitted by this Agreement will be deemed sufficient when delivered personally or by overnight courier or sent by email (with confirmation of receipt) to the relevant address listed on the signature page, or 72 hours after being deposited in the U.S. mail as certified or registered mail with postage prepaid, addressed to the party to be notified at such party’s address listed on the signature page, as subsequently modified by written notice.
(d)Subject and without prejudice to the provisions of Section 4 (Corporate Governance) of this Agreement, this Agreement, does not convey on the holder any right to vote or receive dividends or be deemed the holder of Capital Stock, nor will anything contained herein be construed to confer on the holder of this SAFE, as such, any of the rights of a stockholder of the Company or upon any matter submitted to stockholders at any meeting thereof, or to give or withhold consent to any corporate action or to receive notice of meetings, or to receive subscription rights or otherwise until Capital Stock has been issued upon the terms described herein.
(e)Neither this Agreement nor the rights contained herein may be assigned, by operation of law or otherwise, by either party without the prior written consent of the other; provided, however, that this Agreement and/or the rights contained herein may be assigned without the Company’s consent by the Investor to any Affiliate of the Investor, so long as such Affiliate is not then a person or entity subject to sanction, embargo or trade restriction imposed by the United States government, including, without, limitation, any person or entity on (i) the Consolidated Screening List maintained at www.export.gov and (ii) the U.S. Treasury Department’s Office of Foreign Assets Control sanctions program list.
(f)In the event any one or more of the provisions of this Agreement is for any reason held to be invalid, illegal or unenforceable, in whole or in part or in any respect, or in the event that any one or more of the provisions of this Agreement operate or would prospectively operate to invalidate this Agreement, then and in any such event, such provision(s) only will be deemed null and void and will not affect any other provision of this Agreement and the remaining provisions of this Agreement will remain operative and in full force and effect and will not be affected, prejudiced, or disturbed thereby.
(g)All rights and obligations hereunder will be governed by the laws of the State of Delaware, without regard to the conflicts of law provisions of such jurisdiction.
(h)This Agreement may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, shall be deemed to be an original, and all of which, when taken together, shall constitute but one and the same instrument.
(i)The Company and the Investor intend that this SAFE be treated as an equity instrument in accordance with Section 385(c) of the Internal Revenue Code for U.S. federal income tax purposes, and agree to take positions consistent with the foregoing in their respective applicable tax filings.
(j)The Company and the Shareholders (to the extent of their powers as shareholders of the Company) each, jointly and severally, agrees to indemnify the Investors (and its Affiliates, shareholders, directors, officers, employees, agents, representatives and advisers) for, and defend and hold harmless from and against, any and all damages, losses, suits, claims, deficiencies, actions, proceedings, judgments, losses, expenses, diminution in value and other liabilities of any and every kind, including, without limitation, judgments and costs of settlements, 

SIMPLE AGREEMENT FOR FUTURE EQUITY

including, without limitation, legal fees, (“Losses”) in  each case, arising out of or suffered or incurred in connection with any misrepresentation or any material breach of this Agreement including any representations or warranties made by the Company and/or the Shareholders and all Losses related to any of the foregoing or to enforcement of the provisions hereof. The amount of Losses cannot be higher than the Purchase Amount.
(k)The Investor’s liability to the Company, and the Shareholders arising out of this Agreement, whether in contract, negligence, tort or otherwise, with the exception of fraud, gross negligence or willful misconduct where no such limit will apply, shall be limited to the Purchase Amount in aggregate. The Investor will have no liability to the Company or the Shareholders arising out of this Agreement for any loss or profit, loss of contract, loss of opportunity or any consequential or economic loss in any event.
[SIGNATURE PAGE FOLLOWS]

SIMPLE AGREEMENT FOR FUTURE EQUITY

IN WITNESS WHEREOF, the undersigned have caused this Agreement to be duly executed and delivered on the date first set forth above.

Genome Protection, Inc.

By: /s/Yakov Kogan     
Name: Yakov Kogan
Title: CEO
Address: 73 High Street, Buffalo, NY 14203, USA

Norma Investments Limited

By: /s/Chrystalla Comondrou Stylla                      
Name: Thackery Investments Limited
Title:  Director
Address: Coastal Building, Wickham’s Cay II, P.O. Box 2221, Road Town, Tortola, British Virgin Island. 

Cleveland Biolabs, Inc.

By: /s/Yakov Kogan     
Name: Yakov Kogan
Title: CEO
Address: 73 High Street, Buffalo, NY 14203, USA

Everon Biosciences, Inc.

By: /s/Alexander Polinsky     
Name: Alexander Polinsky
Title: CEO
Address: 640 Ellicott Street, No. 444, Buffalo, New York 14203

SIMPLE AGREEMENT FOR FUTURE EQUITY

Exhibit 1

Intellectual Property Contributed by Everon
	
					
	#
	Subject
	Type of IP
	Reference

	Proof of concept: validity of target and approach for antiaging and anticancer applications

	1
	Pharmacological Stimulation of TLR5 Receptor to Improve Quality of Life and Reduce Frailty
	Invention disclosure and Patent application (Everon)
	Patent Applications\Invention_Disclosure_Flagellin_Everon_April 2018.pdf

	2
	Inhibition of enzymatic activities and targeting of cells with active endogenous reverse transcriptase for prophylaxis and therapy of cancer and aging
	Patent application (Being exclusively licensed by Roswell  Everon)
	Patent Applications\RT RPCI patent application Gudkov_PCT_RT_Ianuary 2018.pdf

	3
	Inhibition of endogenous reverse transcriptase to prevent cancer development and progression towards treatment resistance
	A joint patent application by Everon and Roswell (To be exclusive licensed to Everon) and study report
	Patent Applications\Everon_HRI_Provisional_62687527_June 20, 2018.pdf

	4
	Demonstration of desired biological activity of stavudine and lamivudine (HIV RT inhibitors) in a mouse model of premature aging (Sirt6-knockout mice)
	Proprietary proof of concept; will be published and used for promotion of Everon’s approach
	Manuscript (revised version) under review in Nature

	5
	Everon’s scientific concept on cellular targets for antiaging therapies 
	Company’s confidential presentations 
	Everon antiaging targets.pptx
Retrobiome in cancer and aging.pdf

	2-3. Small molecule inhibitors of RTL1’s polymerase and endonuclease activities

	6
	Technology (RTL1 recombinant protein, proprietary assays) of the high-throughput screening of RTL1 inhibitors and outcome of screening of 260,000 compound libraries
	Basic technology, know-how (Everon)
	Summary - L1RT project_June 2017.pdf ; EBS-L1RT-S-001 L1RT HTS

SIMPLE AGREEMENT FOR FUTURE EQUITY

	
				
	7
	Technology of validation of candidate RTL1 inhibitors in a cell-based assay
	 
	EBS-L1RT-C-002 L1RT Validation of hits in L1 neo RT assay.pdf

	8
	Technology (ENL1 recombinant protein, biochemical readout, proprietary assays) of the high-throughput screening of ENL1 inhibitors and outcome of screening of 260,000 compound libraries
	EBS-L1EN-S-002 L1EN HTS, 2017.pdf; EBS-L1EN-S-003 L1EN HTS 150K, 2018.pdf

	9
	Technology of validation of candidate ENL1 inhibitors in molecular and  cell-based assays
	EBS-L1EN-C-004 L1EN Validation HTS hits.pdf; EBS-L1EN-C-005 L1EN cell-based HTS assay.pdf

	10
	List of chemical structures with applied physico-chemical properties, efficacy against ENL1, in vitro toxicity and an outline of hit-to-lead optimization strategy
	Trade secret and proprietary technology (Everon)
	EBS-L1EN-C-002 Medchem report_EN.pdf

	11
	List of chemical structures with applied physico-chemical properties, efficacy against RTL1, in vitro toxicity and an outline of hit-to-lead optimization strategy
	EBS-L1RT-C-001 Medchem report_RT.pdf

SIMPLE AGREEMENT FOR FUTURE EQUITY

	
				
	12
	Synopsis of protocol of a clinical study of reverse transcriptase inhibitor lamivudine in patients with advanced small cell lung carcinomas (SCLC)
	Clinical trial designed by leading expert physician, Dr. Grace Dy, at Roswell
	SCLC lamivudine trial synopsis_draft.pdf

	4. Vaccine against cells with active LINE1

	13
	Vaccine development plan embedded into overall R&D strategy of Everon
	Basic strategy and technology (Everon)
	R&D Everon Outline 4-30-2018.pdf

	14
	Choice and structure of antigens selected for vaccine preparation
	Trade secret (Everon)
	EBS-L1-V-002 Peptide-based Vaccine.pdf

	5. Clinically feasible methodology that enables assessment of objective biological age and quality of life

	15
	Technology of Frailty Index estimation in preclinical models
	Basic technology know-how (Everon)
	EBS-A-129 Physiological FI, 2017.pdf

	16
	Preliminary results of clinical study on the relationship of selected candidate biomarkers and frailty index and age in humans
	Proprietary know-how, emerging patent application on new biomarkers (Everon)
	Report Diagnostic CT 05-11-2018.pdf

	17
	Description of approach and design of prospective clinical trial of Entolimod in elderly volunteers in Mayo Clinic 
	Presentation of clinical development plan discussed with Dr. Kirkland’s clinical and research team in Mayo Clinic in May 2018 (Everon)
	Mayo visit Plan of Frailty Trial.pdf

SIMPLE AGREEMENT FOR FUTURE EQUITY

Intellectual Property Contributed and/orLicensed by CBLI
CBLI PATENT SCHEDULES

		
	•
	Schedule A1: “Entolimod Composition Patents and Patent Applications”

		
	•
	“Field of Use” means 

		
	•
	This would be sublicensed by CBLI to GP (as CCF is the owner and CBLI is the exclusive licensee)

Schedule A1

	
					
	Title
	Jurisdiction
	Patent Details

	Flagellin related polypeptides and uses thereof
	Europe
	EP 05855104.5
Filing Date: 12-22-2005
Priority Date: 12-22-2004
	EP 1838340
04-04-2018
	ALLOWED

	Flagellin related polypeptides and uses thereof
	Israel
	IL 184140
Filing Date: 12-22-2005
Priority Date: 12-22-2004
	PATENTED

	Flagellin related polypeptides and uses thereof
	Israel
	IL 227910
Filing Date: 12-22-2005
Priority Date: 12-22-2004
	PATENTED

	Flagellin related polypeptides and uses thereof
	Japan
	JP 2007-548451
Filing Date: 12-22-2005
Priority Date: 12-22-2004
	PATENTED

	Flagellin related polypeptides and uses thereof
	USA
	US 11/722,682
Filing Date: 05-02-2008
Priority Date: 12-22-2004
	PATENTED

	Flagellin related polypeptides and uses thereof
	US
	US 13/110,704
Filing Date: 05-18-2011
Priority Date: 12-22-2004
	PATENTED

	Flagellin related polypeptides and uses thereof
	US
	US 13/110,720
Filing Date: 05-18-2011
Priority Date: 12-22-2004
	US 8,287,882
10-16-2012
	PATENTED

	Flagellin related polypeptides and uses thereof
	US
	US 14/284,354
Filing Date: 05-21-2014
Priority Date: 12-22-2004
	PATENTED

	Flagellin related polypeptides and uses thereof
	US
	PATENTED

	Flagellin related polypeptides and uses thereof
	US
	PATENTED

	Flagellin related polypeptides and uses thereof
	US
	PATENTED

	Flagellin related polypeptides and uses thereof
	US
	US 15/254,695
Filing Date: 09-01-2016
Priority Date: 12-22-2004
	PATENTED

	Flagellin related polypeptides and uses thereof
	US
	PENDING

SIMPLE AGREEMENT FOR FUTURE EQUITY

		
	•
	Schedule A2: “Entolimod Oncology Patents and Patent Applications”

		
	•
	Proposed Field: “Field of Use” means 

		
	•
	This would be licensed by CBLI (as owner)

Schedule A2

	
					
	Title
	Jurisdiction
	Patent Details

	Use of toll-like receptor agonist for treating cancer
	Argentina
	AR P120102493
Filing Date: 07-10-2012
Priority Date: 01-10-2011
	N/A
	PENDING

	Use of toll-like receptor agonist for treating cancer
	Israel
	IL 227308
Filing Date: 01-10-2012
Priority Date: 01-10-2011
	PATENTED

	Use of toll-like receptor agonist for treating cancer
	India
	IN 1272/MUMNP/2013
Filing Date: 01-10-2012
Priority Date: 01-10-2011
	PENDING

	Use of toll-like receptor agonist for treating cancer
	Japan
	JP 2013-548628
Filing Date: 01-10-2012
Priority Date: 01-10-2011
	PATENTED

	Use of toll-like receptor agonist for treating cancer
	Mexico
	MX/a/2013/007967
Filing Date: 01-10-2012
Priority Date: 01-10-2011
	PENDING

	Use of toll-like receptor agonist for treating cancer
	New Zealand
	NZ 612615
Filing Date: 01-10-2012
Priority Date: 01-10-2011
	PATENTED

	Use of toll-like receptor agonist for treating cancer
	USA
	US 13/979,104
Filing Date: 07-10-2013
Priority Date: 01-10-2011
	9,376,473
Jun-28-2016
	PATENTED

	Use of toll-like receptor agonist for treating cancer
	USA
	US 15/631,427
Filing Date: 23-Jun-2017
Priority Date: 01-10-2011
	N/A
	ALLOWED

SIMPLE AGREEMENT FOR FUTURE EQUITY

		
	•
	Schedule A3: “Super Entolimod (GP532) Patents and Patent Applications”

		
	•
	Proposed Field: “Field of Use” means 

		
	•
	This would be assigned by CBLI (as owner) with license back for ARS 

Schedule A3

	
					
	Title
	Jurisdiction
	Patent Details

	Flagellin compositions
	Australia
	2015296555
Filing Date: 07-29-2015
Priority Date: 07-30-2014
	N/A
	Pending

	Flagellin compositions
	Brazil
	BR 11 2017 001796 2
Filing Date: 07-29-2015
Priority Date: 07-30-2014
	Pending

	Flagellin compositions
	Canada
	2,994,218
Filing Date: 07-29-2015
Priority Date: 07-30-2014
	Pending

	Flagellin compositions
	China
	2015800486281 
Filing Date: 07-29-2015
Priority Date: 07-30-2014
	Pending

	Flagellin compositions
	Eurasia
	201790273
Filing Date: 07-29-2015
Priority Date: 07-30-2014
	Pending

	Flagellin compositions
	Europe
	15 827 248.4 
Filing Date: 07-29-2015
Priority Date: 07-30-2014
	Pending

	Flagellin compositions
	Hong Kong
	17112073.6
Filing Date: 07-29-2015
Priority Date: 07-30-2014
	N/A
	Pending

	Flagellin compositions
	Israel
	250334
Filing Date: 07-29-2015
Priority Date: 07-30-2014
	Pending

	Flagellin compositions
	India
	Pending

	Flagellin compositions
	Japan
	Pending

	Flagellin compositions
	Korea
	Pending

	Flagellin compositions
	Mexico
	MX/a/2017/001279
Filing Date: 07-29-2015
Priority Date: 07-30-2014
	Pending

	Flagellin compositions
	USA
	Pending

	Flagellin compositions
	South Africa
	2017/01286 
Filing Date: 07-29-2015
Priority Date: 07-30-2014
	Pending

SIMPLE AGREEMENT FOR FUTURE EQUITY

		
	•
	Schedule A4: “Entolimod Vaccine Patents and Patent Applications”

		
	•
	Proposed Field: “Field of Use” means all fields.  

		
	•
	This would be assigned  by CBLI (as owner)

Schedule A4

	
					
	Title
	Jurisdiction
	Patent Details

	Flagellin compositions and uses including effective vaccination
	Australia
	2015296298 
Filing Date: 07/30/2015
Priority Date: 07-30-2014
	N/A
	Pending

	Flagellin compositions and uses including effective vaccination
	Canada
	2,994,289
Filing Date: 07/30/2015
Priority Date: 07-30-2014
	Pending

	Flagellin compositions and uses including effective vaccination
	China
	2015800528424 
Filing Date: 07/30/2015
Priority Date: 07-30-2014
	Pending

	Flagellin compositions and uses including effective vaccination
	Eurasia
	201790294 
Filing Date: 07/30/2015
Priority Date: 07-30-2014
	Pending

	Flagellin compositions and uses including effective vaccination
	Europe
	15 827 000.9 
Filing Date: 07/30/2015
Priority Date: 07-30-2014
	Pending

	Flagellin compositions and uses including effective vaccination
	Israel
	250331
Filing Date: 07/30/2015
Priority Date: 07-30-2014
	Pending

	Flagellin compositions and uses including effective vaccination
	Japan
	2017504354
Filing Date: 07/30/2015
Priority Date: 07-30-2014
	N/A
	Pending

	Flagellin compositions and uses including effective vaccination
	Mexico
	MX/a/2017/001406
Filing Date: 07/30/2015
Priority Date: 07-30-2014
	N/A
	Pending

	Flagellin compositions and uses including effective vaccination
	USA
	15/500,133 
Filing Date: 07/30/2015
Priority Date: 07-30-2014
	N/A
	Pending

SIMPLE AGREEMENT FOR FUTURE EQUITY

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00286-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00286-of-00352.parquet"}]]